Edgewise Therapeutics, Inc.

NASDAQ (USD): Edgewise Therapeutics, Inc. (EWTX)

Last Price

36.38

Today's Change

+0.95 (2.68%)

Day's Change

34.79 - 36.70

Trading Volume

603,723

Profile
EWTX

Exchange:  NASDAQ Global Select NASDAQ Global Select

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Dr. Kevin Koch Ph.D. Dr. Kevin Koch Ph.D.

Full Time Employees:  97 97

IPO Date:  2021-03-26 2021-03-26

CIK:  0001710072 0001710072

ISIN:  US28036F1057 US28036F1057

CUSIP:  28036F105 28036F105

Beta:  0.15 0.15

Last Dividend:  0.00 0.00

Dcf Diff:  35.11 35.11

Dcf:  1.27 1.27

Description

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Address

3415 Colorado Avenue,
Boulder, CO 80303, US

303 735 8373

http://www.edgewisetx.com

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment